Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher


Matthias Holdhoff, M.D., Ph.D.

Photo of Dr. Matthias Holdhoff, M.D., Ph.D.
  • Associate Professor of Oncology

Languages: English, German


Brain Cancer, Brain Tumors, Medical Oncology, Neuro-Oncology, Primary central nervous system (CNS) lymphoma

Research Interests

Clinical Trials in Primary Brain Cancers; Translational Research in Neuro-Oncology

Request an Appointment

Insurance Information



Outside of Maryland

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8964

Sibley Memorial Hospital

Appointment Phone: 202-660-6500
5255 Loughboro Road, NW
1st Floor
Washington, DC 20016 map
Fax: 202-660-6501


Dr. Matthias Holdhoff is a medical oncologist in the Brain Cancer Program at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as well as assistant professor of oncology and neurological surgery at Johns Hopkins University School of Medicine.  Dr. Holdhoff’s expertise is on primary brain cancers and central nervous system lymphomas.  He practices out of the Sidney Kimmel Comprehensive at Johns Hopkins Hospital in Baltimore and he has a clinic at Sibley Memorial Hospital in Washington, DC.  He is board certified in internal medicine and medical oncology.  

Dr. Holdhoff earned his medical degree from Freie Universität Berlin and received his doctorate degree at Charité University Medicine Berlin. He completed a residency in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training within the Ludwig Center for Cancer Genetics and Therapeutics (Vogelstein lab).

Dr. Holdhoff is a clinical translational investigator in neuro-oncology.  His research is focused on novel trials in malignant gliomas, including glioblastomas, and on translational biomarker research in brain cancers.  He has led and contributed to numerous clinical trials, publications and presentations.  

Dr. Holdhoff is panel member for the National Comprehensive Cancer Network’s guidelines for cancers of the central nervous system. He was recipient of a 2010 ASCO Young Investigator Award and Merit Award and he was awarded the Director’s Teaching Award in Clinical Sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.  He is faculty on the Janeway firm of the Osler Internal Medicine Residency Program at Johns Hopkins Hospital. more


  • Associate Professor of Oncology
  • Associate Professor of Neurosurgery
  • Joint Appointment in Medicine

Departments / Divisions

Centers & Institutes



  • MD, Freie Universitat Berlin (2003)


  • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)


  • Johns Hopkins University School of Medicine / Oncology (2010)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2007)
  • American Board of Internal Medicine / Oncology (2009)

Research & Publications

Research Summary

Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology.  His clinical research is concentrated on early phase therapeutic clinical trials in malignant gliomas, including glioblastomas.  He is leading or participating in multiple brain cancer trials, including within the Adult Brain Tumor Consortium.  In addition, he is working on novel biomarkers to assess response and disease activity in malignant gliomas.

Selected Publications

View all on Pubmed

Staedtke V, a Dzaye OD, Holdhoff M. Actionable Molecular Biomarkers in Primary Brain Tumors. Trends in Cancer 2016 [published online ahead of print]

Lange RP, Everett A, Dulloor P, Korley FK, Bettegowda C, Blair C, Grossman SA, Holdhoff M. Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas. Cancer Invest. 2014 Oct;32(8):423-9. PMID:25019213

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014 Jul 15;83(3):235-9. PMID:24928128

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. PMID:24553385

Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas.Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, Diaz LA Jr. J Neurooncol. 2012 Nov;110(2):279-85. PMID:22930388

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button